|12th January 2021||David P Hochman||15,741||Grant/award etc.||$0.00|
|21st December 2020||Sean F. Moran||87,500||Exercise of derivative||$1.40||$122,500.00|
|21st December 2020||Sean F. Moran||87,500||Open or private sale||$1.75||$153,125.00|
|18th December 2020||Sean F. Moran||53,610||Exercise of derivative||$1.00||$53,610.00|
|18th December 2020||Sean F. Moran||53,610||Open or private sale||$1.40||$75,054.00|
|16th December 2020||Sean F. Moran||36,923||Open or private sale||$1.32||$48,627.59|
|16th December 2020||Sean F. Moran||36,923||Exercise of derivative||$0.17||$6,118.14|
|4th December 2020||David P Hochman||5,000||Open or private purchase||$0.99||$4,965.00|
|11th November 2020||Yuval Cohen||4,240||Open or private purchase||$1.21||$5,126.16|
|12th October 2020||David P Hochman||18,466||Grant/award etc.||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. The company was founded on December 18, 2013.